Krystal Biotech, Inc. ($KRYS)
Filing Information
| Accession Number | 0001711279-26-000021 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 26, 2026 |
| Document | View SEC Filing |
Transactions
22
Total Shares
135,951
Total Value
$16,242,604.80
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | Feb 24, 2026 | Exercise/Conversion | 37,895 | $2.46 | $93,221.70 | 37,895 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 569 | $262.91 | $149,594.08 | 37,326 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 1,733 | $264.12 | $457,727.93 | 35,593 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 3,557 | $265.08 | $942,878.18 | 32,036 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 8,986 | $266.18 | $2,391,885.39 | 23,050 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 11,673 | $266.97 | $3,116,310.46 | 11,377 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 6,671 | $268.04 | $1,788,079.50 | 4,706 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 3,963 | $268.97 | $1,065,923.75 | 743 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 370 | $269.83 | $99,836.43 | 373 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 373 | $271.09 | $101,117.99 | 0 | Direct | โ | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 62 | $263.05 | $16,309.17 | 107,300 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 900 | $264.60 | $238,136.04 | 106,400 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 1,604 | $265.54 | $425,919.10 | 104,796 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 4,339 | $266.62 | $1,156,878.93 | 100,457 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 1,891 | $267.37 | $505,596.67 | 98,566 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 1,674 | $268.67 | $449,746.88 | 96,892 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 930 | $269.50 | $250,636.21 | 95,962 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 24, 2026 | Sale | 2,425 | $274.90 | $666,626.92 | 93,537 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 25, 2026 | Sale | 700 | $275.00 | $192,500.00 | 92,837 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 26, 2026 | Sale | 5,103 | $275.28 | $1,404,759.96 | 87,734 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Common Stock | โ | Feb 26, 2026 | Sale | 2,638 | $276.32 | $728,919.50 | 85,096 | Indirect | Directly beneficially owned by Alta Bioequities, L.P. | View Details | |
Director | Stock Option (Right to Buy) | Derivative | Feb 24, 2026 | Exercise/Conversion | 37,895 | $0.00 | $0.00 | 0 | Direct | โ | View Details |